Biotech4 months ago
PharmaMar Reduces its Profit by 45% in Q1, Rovi Reduces Income by 14%
PharmaMar's turnover rose 0.8% in H1 2024, reaching €80.8 million, with oncology sales down 3.2%. Royalty income increased by 16%, while non-recurring income slightly declined. R&D...